157 related articles for article (PubMed ID: 36992807)
21. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer.
Kim M; Kim WG; Oh HS; Park S; Kwon H; Song DE; Kim TY; Shong YK; Kim WB; Sung TY; Jeon MJ
Thyroid; 2017 Sep; 27(9):1149-1155. PubMed ID: 28635571
[TBL] [Abstract][Full Text] [Related]
22. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
[TBL] [Abstract][Full Text] [Related]
23. Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome.
Ciappuccini R; Heutte N; Lasne-Cardon A; Saguet-Rysanek V; Leroy C; Le Hénaff V; Vaur D; Babin E; Bardet S
BMC Cancer; 2020 Aug; 20(1):765. PubMed ID: 32799836
[TBL] [Abstract][Full Text] [Related]
24. Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer: Is Total Thyroidectomy Necessary for Patients at Any Risk?
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Tomoda C; Hames KY; Akaishi J; Masaki C; Ito K
Thyroid; 2020 Apr; 30(4):548-556. PubMed ID: 31910105
[No Abstract] [Full Text] [Related]
25. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
26. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
27. Prognostic Utility of Tumor Stage versus American Thyroid Association Risk Class in Thyroid Cancer.
Abiri A; Pang J; Prasad KR; Goshtasbi K; Kuan EC; Armstrong WB; Haidar YM; Tjoa T
Laryngoscope; 2023 Jan; 133(1):205-211. PubMed ID: 35716358
[TBL] [Abstract][Full Text] [Related]
28. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan.
Hassan A; Razi M; Riaz S; Khalid M; Nawaz MK; Syed AA; Bashir H
Clin Nucl Med; 2016 Aug; 41(8):606-13. PubMed ID: 27124680
[TBL] [Abstract][Full Text] [Related]
29. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
30. Survival in differentiated thyroid carcinoma: Comparison between the 7th and 8th editions of the AJCC/UICC TNM staging system and the ATA initial risk stratification system.
Cavalheiro BG; de Matos LL; Leite AKN; Kulcsar MAV; Cernea CR; Kowalski LP
Head Neck; 2021 Oct; 43(10):2913-2922. PubMed ID: 34062032
[TBL] [Abstract][Full Text] [Related]
31. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
32. Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer.
Ghaznavi SA; Ganly I; Shaha AR; English C; Wills J; Tuttle RM
Thyroid; 2018 Oct; 28(10):1293-1300. PubMed ID: 29897011
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
34. Differentiated Thyroid Cancer in a Pediatric Population: Estimating the Risk of Recurrence and Evolution Over Time.
Damásio I; Dias D; Pinheiro S; Esteves S; Leite V; Santos R
Cureus; 2023 Jan; 15(1):e34313. PubMed ID: 36860222
[TBL] [Abstract][Full Text] [Related]
35. Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer.
Redlich A; Luster M; Lorenz K; Lessel L; Rohrer TR; Schmid KW; Frühwald MC; Vorwerk P; Kuhlen M
J Clin Endocrinol Metab; 2022 Jan; 107(1):e165-e177. PubMed ID: 34415989
[TBL] [Abstract][Full Text] [Related]
36. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
37. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
38. Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis.
Kim M; Kim WG; Jeon MJ; Kim HK; Yi HS; Kim ES; Kim BH; Kim WB; Shong YK; Kang HC; Kim TY
Endocrinol Metab (Seoul); 2020 Mar; 35(1):149-156. PubMed ID: 32207275
[TBL] [Abstract][Full Text] [Related]
39. Combination of initial stimulation thyroglobulins and staging system by revised ATA guidelines can elaborately discriminate prognosis of patients with differentiated thyroid carcinoma after high-dose remnant ablation.
Kim MH; Ko SH; Bae JS; Lim DJ; Baek KH; Lee JM; Kang MI; Cha BY
Clin Nucl Med; 2012 Nov; 37(11):1069-74. PubMed ID: 22996253
[TBL] [Abstract][Full Text] [Related]
40. Comparison of staging and recurrence predictors in patients with differentiated thyroid cancer between the 7th and 8th editions of the American Joint Committee on Cancer staging systems.
Elbasan O; Gogas Yavuz D
Minerva Endocrinol (Torino); 2023 Sep; 48(3):261-273. PubMed ID: 36756784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
